Abstract：Objective: To study the effect of nicorandil combined with trimetazidine on serum high sensitive C reactive protein(hs-CRP), endothelial cell specific molecules-1(ESM-1), endothelial cell particles (EMPs) and in patients with acute myocardial infarction after emergency percutaneous coronary intervention(PCI). Methods: 92 patients of acute myocardial infarction received therapy from October 2015 to October 2017 in our hospital were selected as research objects. According to random number table, those patients were divided into the observation group (n=46) and the control group (n=46), they were performed emergency PCI operation, and were given routine treatment during the perioperative period, the control group was treated with trimetazidine, while the observation group was combined with nicorandil, continuous use of 7 days. The electrocardiogram effect, the changes of cardiac function, hs-CRP, ESM-1 and EMPs before PCI and after treatment 7 days were compared between the two groups, and the incidence of adverse cardiovascular events in the after operation 30d was compared. Results: After 7 days treatment, the total effective rate in the observation group was 93.48% (43/46), which was significantly higher than that of the control group 73.91% (34/46) (P<0.05); after 7d treatment, the index of cardiac function in the two groups was significantly improved than that before PCI (P<0.05), and the left ventricular end diastolic diameter (LVDD), left ventricular end systolic diameter (LVDS), left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) in the observation group were significantly lower than those in the control group, the left ventricular ejection fraction (LVEF) was significantly higher than those in the control group (P<0.05); after treatment 7d, the serum hs-CRP, ESM-1, and EMPs in the two groups were significantly lower than those before the PCI (P<0.05), and the serum hs-CRP, ESM-1 and EMPs in the observation group were significantly lower than those in the control group[(6.84±1.19)mg/L vs(8.94±1.46)mg/L,(0.89±0.11)μg/L vs(1.16±0.15)μg/L,(820.18±113.49)number/μL vs(1017.35±120.47)number/μL](P<0.05); the total incidence of emergency coronary artery revascularization, recurrent myocardial infarction, stroke and cardiogenic death in the two groups was 4.35% and 13.04%, there was no significant difference (P＞0.05). Conclusion: Nicorandil combined with trimetazidine is well for acute myocardial infarction after PCI, which can effectively improve the postoperative cardiac function, and the short-term prognosis is good, it's intrinsic mechanism may reduce the expression of serum hs-CRP, ESM-1 and EMPs.
王奇胜, 王少波, 段运祥. 尼可地尔联合曲美他嗪对AMI患者急诊PCI术后血清hs-CRP ESM-1 EMPs的影响[J]. 河北医学, 2018, 24(7): 1072-1077.
WANG Qisheng, WANG Shaobo, DUAN Yunxiang. Effect of Nicorandil combined with Trimetazidine on Serum hs-CRP ESM-1 EMPs of Emergency Patients with AMI After PCI. HeBei Med, 2018, 24(7): 1072-1077.
[1] 霍勇,傅向华,葛均波,等.急性ST段抬高型心肌梗死溶栓治疗的合理用药指南[J].中国医学前沿杂志(电子版),2016,8(8):25~41. [2] Niccoli G, Calvieri C, Minelli S, et al. Permanent polymer of drug eluting stents increases eosinophil cationic protein levels following percutaneous coronary intervention independently of C-reactive protein[J]. Atherosclerosis, 2014, 237(2): 816~820. [3] Andrukhov O, Gemperli AC, Tang Y, et al. Effect of different enamel matrix derivative proteins on behavior and differentiation of endothelial cells[J]. Dent Mater, 2015, 31(7): 822~832. [4] 王婷,李结华.曲美他嗪对经皮冠状动脉介入治疗急性心肌梗死患者的影响[J].中国循证心血管医学杂志,2015,7(5):619~621 [5] Suleimani HF, Eshraghi A, Daloee MH, et al. Effect of nicorandil on QT dispersion in patients with stable angina pectoris undergoing elective angioplasty: A triple-blind, randomized, placebo-controlled study[J]. Electron Physician, 2017, 9(8): 4934~4941. [6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675~690. [7] 葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013.164~166. [8] Lonborg J, Engstrom T, Ahtarovski KA, et al. Myocardial damage in patients with deferred stenting after STEMI: A DANAMI-3-DEFER substudy[J].Am Coll Cardiol, 2017, 69(23): 2794~2804. [9] Wu H, Ye M, Yang J, et al. Nicorandil protects the heart from ischemia/reperfusion injury by attenuating endoplasmic reticulum response-induced apoptosis through PI3K/Akt signaling pathway[J]. Cell Physiol Biochem, 2015, 35(6): 2320~2332. [10] 郑相慧,武维恒,巩雷,等.急性冠状动脉综合征患者相关炎性因子水平变化及临床意义[J].中华老年心脑血管病杂志,2015,17(3):253~257. [11] Raudszus B, Mulac D, Langer K. A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells[J]. Int Pharm, 2017, 536(1): 211~221. [12] Iranirad L, Hejazi SF, Sadeghi MS, et al. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: a prospective randomized controlled trial[J]. Cardiol, 2017, 24(5): 502~507. [13] Aizawa K, Takahari Y, Higashijima N, et al. Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation[J].Pharmacol Sci, 2015, 127(3): 284~291.
2018, Vol. 24 
冀公网安备13080202000677号